Meeting
2015 Gastrointestinal Cancers Symposium
Do recurrent and de novo metastatic biliary tract cancer patients have the same outcome on treatment?
Authors
Mairead G McNamara
The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom
Mairead G McNamara , Priya Aneja , Manjula Maganti , Anne M. Horgan , Sean P. Cleary , Jennifer J. Knox
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 351)
DOI
10.1200/jco.2015.33.3_suppl.351
Abstract #
351
Poster Bd #
C20
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
First Author: Jin Won Kim
Poster
2023 ASCO Annual Meeting
Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
First Author: Hai-Qiang Mai
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer